Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Sysa-Shah, P; Tocchetti, CG; Gupta, M; Rainer, PP; Shen, X; Kang, BH; Belmonte, F; Li, J; Xu, Y; Guo, X; Bedja, D; Gao, WD; Paolocci, N; Rath, R; Sawyer, DB; Naga Prasad, SV; Gabrielson, K.
Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways.
Cardiovasc Res. 2016; 109(3):358-373 Doi: 10.1093/cvr/cvv274 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Rainer Peter

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Despite the observation that ErbB2 regulates sensitivity of the heart to doxorubicin or ErbB2-targeted cancer therapies, mechanisms that regulate ErbB2 expression and activity have not been studied. Since isoproterenol up-regulates ErbB2 in kidney and salivary glands and β2AR and ErbB2 complex in brain and heart, we hypothesized that β-adrenergic receptors (AR) modulate ErbB2 signalling status. ErbB2 transfection of HEK293 cells up-regulates β2AR, and β2AR transfection of HEK293 up-regulates ErbB2. Interestingly, cardiomyocytes isolated from myocyte-specific ErbB2-overexpressing (ErbB2(tg)) mice have amplified response to selective β2-agonist zinterol, and right ventricular trabeculae baseline force generation is markedly reduced with β2-antagonist ICI-118 551. Consistently, receptor binding assays and western blotting demonstrate that β2ARs levels are markedly increased in ErbB2(tg) myocardium and reduced by EGFR/ErbB2 inhibitor, lapatinib. Intriguingly, acute treatment of mice with β1- and β2-AR agonist isoproterenol resulted in myocardial ErbB2 increase, while inhibition with either β1- or β2-AR antagonist did not completely prevent isoproterenol-induced ErbB2 expression. Furthermore, inhibition of ErbB2 kinase predisposed mice hearts to injury from chronic isoproterenol treatment while significantly reducing isoproterenol-induced pAKT and pERK levels, suggesting ErbB2's role in transactivation in the heart. Our studies show that myocardial ErbB2 and βAR signalling are linked in a feedback loop with βAR activation leading to increased ErbB2 expression and activity, and increased ErbB2 activity regulating β2AR expression. Most importantly, ErbB2 kinase activity is crucial for cardioprotection in the setting of β-adrenergic stress, suggesting that this mechanism is important in the pathophysiology and treatment of cardiomyopathy induced by ErbB2-targeting antineoplastic drugs. Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email:
Find related publications in this database (using NLM MeSH Indexing)
Adrenergic beta-Agonists - pharmacology
Animals -
Cyclic AMP - metabolism
Female -
Heart Ventricles - drug effects
Heart Ventricles - metabolism
Isoproterenol - pharmacology
Mice -
Myocardium - metabolism
Myocytes, Cardiac - drug effects
Myocytes, Cardiac - metabolism
Receptor, ErbB-2 - genetics
Receptor, ErbB-2 - metabolism
Receptors, Adrenergic, beta-1 - metabolism
Signal Transduction - drug effects
Signal Transduction - physiology

Find related publications in this database (Keywords)
ErbB2 kinase inhibitors
beta-Adrenergic stimulation
© Med Uni Graz Impressum